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Abstract  
The extremely high diversity of organisms present in our oceans has led 
researchers to give great importance to the marine environment as a source of natural 
products. Marine cyanobacteria, in particular, are known for their ability to synthesize 
secondary metabolites with potential for novel drug discovery in the treatment of several 
human diseases. A large number of studies already performed in these organisms have 
been mainly focused on the filamentous and colonial forms. They revealed a high variety 
of compounds with anticancer activity while many cyanobacterial genera, namely 
unicellular free-living forms, have been largely overlooked. Studies on the bioactivity of 
these less studied genera have recently been performed at the Laboratory of 
Ecotoxicology Genomics and Evolution, LEGE – CIIMAR, revealing promising results. In 
this work, we aimed to isolate and characterize novel compounds from unicellular free-
living species using a bioassay-guided isolation approach. Cytotoxicity of strains/fractions 
was studied on the RKO, MG63 and T47D cancer cell lines and the isolation of the 
compounds was guided by the bioactivity in these cancer cells. To complement bioactivity 
search, enzyme inhibition and antimicrobial assays were also performed. Partial 
characterization of the isolated compounds was achieved by Nuclear Magnetic 
Resonance spectroscopy and Liquid Chromatography – Mass Spectrometry. 
Cyanobacterial cultures were performed and extracts were obtained from 
lyophilized biomass. In vitro cultures of the human cell lines were also established. The 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to 
evaluate the cellular viability of cancer cells exposed to the different fractions obtained. 
IC50 values of the compounds were calculated by testing a range of concentrations in the 
same cancer cell lines. Isolation of the compounds was performed by wet chemistry 
extraction techniques and HPLC.  
The MTT results revealed several sub-fractions which induced a decrease in cells 
viability for the Synechocystis salina LEGE 06099 strain. The enzymatic and antimicrobial 
assays revealed no activity from each fraction of this strain. Thus, following only MTT 
activity we were able to isolate several different compounds and to partially characterize 
their structure. Compounds F-5.4 and F-6.2.1 revealed moderate toxicity to these tested 
cell lines, being the T47D the most sensitive.  
Another strain was used, uncultured Chroococcales LEGE 10410 strain, and 
molecular identification through the 16S rRNA gene revealed that this strain belonged to 
the genus Chroococcidiopsis. The MTT results revealed no significant bioactivity, while 
the enzymatic and antimicrobial assays showed interesting results for some fractions. 
However, further fractionation and isolation of these fractions is necessary.  
vi 
 
Here, we discovered a family of novel compounds obtained from the 
cyanobacterial strain Synechocystis salina LEGE 06099 with moderate anticancer activity, 
although further analysis on their structure is necessary.   
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Resumo 
A elevada diversidade de espécies marinhas presente nos nossos oceanos levou 
os investigadores a dar grande importância ao ambiente marinho como fonte de novos 
produtos naturais. Em particular, as cianobactérias marinhas são conhecidas pela sua 
capacidade de sintetizar metabolitos secundários com potencial para a descoberta de 
novas drogas no tratamento de diversas doenças humanas, incluindo o cancro. O 
elevado número de estudos já feitos para estes organismos têm dado principal destaque 
às espécies filamentosas e coloniais. Estas revelaram uma grande variedade de 
compostos com actividade anti-cancerígena, enquanto vários géneros de cianobactérias, 
nomeadamente os géneros unicelulares de vida livre, têm sido amplamente 
negligenciados. Estudos sobre a actividade biológica destas espécies menos estudadas 
têm sido realizados no Laboratório de Ecotoxicologia, Genómica e Evolução LEGE – 
CIIMAR e revelaram resultados interessantes. Neste trabalho, os principais objectivos 
foram isolar e caracterizar novos compostos de espécies unicelulares de vida livre 
usando uma abordagem de isolamento guiada por bioensaios. A citotoxicidade das 
fracções foi examinada nas linhagens cancerígenas humanas RKO, MG63 e T47D e o 
isolamento dos compostos seguiu a actividade observada nestas células. Para 
complementar a procura por bioactividade, foram também utilizados ensaios enzimáticos 
e antimicrobianos. A caracterização estrutural parcial dos compostos isolados foi 
realizada por Ressonância Magnética Nuclear e Cromatografia Líquida – Espectrometria 
de Massa. 
Realizaram-se culturas de cianobactérias e os seus extractos brutos foram obtidos 
a partir da biomassa liofilizada. As linhagens tumorais foram mantidas em culturas in 
vitro. O teste de brometo 3-(4.5-dimetiltiaziol-2-il)-2.5-difeniltetrazolio (MTT) foi usado 
para avaliar a viabilidade celular das células cancerígenas expostas às diferentes 
fracções obtidas. O IC50 dos compostos foi calculado para as mesmas linhagens 
celulares usando um intervalo de concentrações conhecidas. O isolamento dos 
compostos foi realizado por técnicas aquosas de extracção química e HPLC.    
Os resultados do ensaio MTT revelaram várias sub-fracções que induziram um 
decréscimo na viabilidade celular para a estirpe Synechocystis salina LEGE 06099. Os 
ensaios enzimáticos e antimicrobianos não revelaram bioactividade para nenhuma das 
fracções. Seguindo a actividade biológica registada pelo ensaio MTT conseguiram-se 
isolar diferentes compostos e caracterizar parcialmente as suas estruturas. Os compostos 
F-5.4 e F-6.2.1 revelaram toxicidade moderada nas diferentes linhas celulares, sendo que 
a linha T47D revelou ser a mais sensível. 
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Para além da estirpe LEGE 06099, foi também usada a estirpe desconhecida 
Chroococcales LEGE 10410 e através da análise molecular do gene 16S rRNA 
identificou-se como pertencendo ao género Chroococcidiopsis. Os resultados do ensaio 
MTT não revelaram actividade significativa para nenhuma das fracções testadas 
enquanto os ensaios enzimáticos e antimicrobianos revelaram algumas fracções 
interessantes. Contudo, é necessário continuar o fraccionamento e possível isolamento 
de compostos desta estirpe. 
Aqui, descobrimos uma família de novos compostos com actividade anti-
cancerígena obtidos a partir de S. salina LEGE 06099, embora análise mais detalhada 
sobre as suas estruturas seja necessária.  
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1. Introduction 
 
Over the last century, natural products have been an extremely rich source of 
drugs and structural templates for starting materials with exceptional importance for drug 
discovery for the treatment of infectious, neurological, cardiovascular, immunological, 
inflammatory and oncological human diseases (Butler, 2008; Newman and Cragg, 2012). 
The importance of such natural products is also remarkable as they can give rise to 
synthetic analogues with improved pharmacological and pharmacokinetic properties  
(Newman and Cragg, 2012). Natural products usually show pharmacological or biological 
activity and are produced by a large variety of living organisms, such as plants, 
invertebrates, fungi and bacteria (Mishra and Tiwari, 2011). The extremely high diversity 
of organisms present in our oceans has led researchers to consider the marine 
environment as a very rich source of natural products (Gerwick and Moore, 2012).  
Marine organisms such as mollusks, sponges, tunicates, cnidarians, red, brown 
and green macroalgae, phytoplankton and bacteria (including cyanobacteria) have been 
the most studied in the research area of bioactive compounds (Blunt et al., 2013). From 
some of these groups, several success cases of natural compounds that were developed 
into therapeutics have been described (Table 1). Besides already FDA-Approved agents, 
other marine natural products inspired compounds are currently undergoing phase I, II 
and III clinical trials (Mayer et al., 2010). 
 
Table 1 – Five marine natural products that are FDA-Approved Agents. Adapted from 
Gerwick and Moore, 2012. 
Compound name 
Collected source 
organism 
Predicted 
biosynthetic source 
Disease area 
Cytarabine (Ara-C) Sponge Bacterium Cancer 
Viadarabine (Ara-A) Sponge Bacterium Antiviral 
Ziconotide Cone snails Mollusks Pain 
Trabectedin (ET-743) Tunicate Bacterium Cancer 
Brentuximab vedotin 
(SGN-35) 
Mollusk Cyanobacterium Cancer 
  
Although many of the marine natural compounds have been collected from 
sponges, tunicates or mollusks, it has been shown, or there is a strong suspicion that the 
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actual producers of these bioactive compounds are some of the microorganism species 
that they harbor, or of which they feed on (Gerwick and Moore, 2012).  
Among microorganisms, bacteria are the most prolific species, thus being called 
the jewels of the world’s ocean and accounting for the highest part of clinical trial and 
approved pharmaceutical drugs (Figure 1) (Gerwick and Moore, 2012). 
 
Figure 1 – 20 Marine-derived drugs and clinical trial agents divided by their subsequently 
shown or predicted source organisms (20 total) (Adapted from Gerwick and Moore, 2012). 
 
From the microbial world, cyanobacteria were found to be an exceptionally prolific 
source of secondary metabolites, and continue to be a main biological source for the 
discovery of lead compounds for drug discovery (Dixit and Suseela, 2013).  
 
1.1. Cyanobacteria 
 
Cyanobacteria are prokaryotic gram-negative organisms that have the ability to 
perform photosynthesis. As gram-negatives, cyanobacteria have a layered and complex 
cell wall constituted by a thin peptidoglycan layer and periplasmic space between the 
inner cytoplasmic membrane and the outer cell membrane. This peptidoglycan layer is, 
however, thicker in cyanobacteria than in other gram-negative bacteria (Hoiczyk & Hansel, 
2000). The outer membrane is chemically characterized by the presence of 
lipopolysaccharides (LPS), phospholipids and proteins while the periplasmic space is gel-
like in consistency due to its composition of a high concentration of proteins and enzymes 
for nutrient acquisition, peptidoglycan synthesis and modification of toxic compounds 
(Madigan et al., 2003).  
Cyanobacteria (4)
Bacteria (12)
Fungi (1)
Microalgae (1)
Macroorganisms (2)
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Regarding morphology, cyanobacteria can be unicellular (free living), colonial or 
filamentous. Photosynthetic reactions take place in the internal thylakoids, which are a 
membrane system with photosynthetic pigments. Cyanobacteria reproduce asexually by 
fission, fragmentation, hormogonia or akinete germination (Ferreira and Sousa, 1998). 
Cyanobacteria are the only oxygenic photosynthetic bacteria, with photosystems 
(PSI and PSII), using H2O as a photoreductant in the electron transport chain and 
consuming CO2 as a carbon source (Castenholz and Boone, 2001). Furthermore, 
cyanobacteria can also be anaerobic photoautotrophs using H2S, thiosulfate, or H2 as 
alternative electron donors and can also perform nitrogen fixation (Whitton & Potts, 2002; 
Cohen & Gurevitz, 2006). 
Organisms of this prokaryotic group have been found in most of the natural 
illuminated environments known so far, including terrestrial, freshwater and marine 
ecosystems. This wide distribution across the world reflects a large variety of species 
capable to adapt to numerous environmental conditions, much of them extreme, such as 
ice fields, deserts or hot springs, where they can survive and thrive (Biondi et al., 2008; 
Vasconcelos, 2006). For certain genera, this adaptation to adverse conditions can be 
explained by the presence of specialized cyanobacterial cells such as heterocysts, which 
are used for nitrogen fixation in nitrogen depleted environments and/or akinetes, which 
have the capacity to store reserve substances and protect the organism during periods of 
darkness, dessication or cold (Ferreira & Sousa, 1998; Madigan et al., 2003).      
The aquatic environment is where the cyanobacteria are more prevalent. These 
organisms are common in freshwater, brackish and marine environments around the 
globe where they can exist in either benthic or planktonic communities. For many years, 
cyanobacteria have been the subject of innumerous studies due to their negative impacts 
on freshwater ecosystems, where they can form harmful blooms causing severe changes 
in water quality and because they have the ability to release toxins (Vasconcelos, 2006; 
Martins et al., 2005). However, in more recent years, the study of marine cyanobacteria 
has come into focus, mainly due to their potential to produce very interesting natural 
compounds with biological activity and with high potential as pharmacological agents 
(Nunnery et al., 2010).  
 
1.2 Bioactive compounds from marine cyanobacteria  
 
Overall, cyanobacteria have been recognized as harmful to a large variety of 
organisms due to the potential production of toxic compounds, such as hepatotoxins, 
neurotoxins, cytotoxins, among others (Bláha et al., 2009). However, an increased 
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number of studies regarding marine cyanobacteria capability to produce bioactive 
compounds that are pharmacologically interesting for the treatment of human diseases, 
have been performed (Nunnery et al., 2010; Uzair et al., 2012; Dixit and Suseela, 2013). 
For this reason, several bioactive compounds from these organisms were described 
where activity as antibacterial, anti-inflammatory, antiviral, antifungal, algaecides and in 
the particular case of this work, anticancer agents have been found (Figure 2) (Schlegel et 
al., 1999; Martins et al., 2008; Mayer et al., 2011; Costa et al., 2012; Rath & 
Priyadarshani, 2013). 
 
 
Figure 2 – Biological activity of 128 isolated compounds from marine cyanobacteria (Tan, 
2007).  
 
To date, most compounds have been isolated from the orders Oscillatoriales and 
Nostocales, followed by Chroococcales and Stigonematales, while only few compounds 
from the order Pleurocapsales were described (Tidgewell et al., 2010). Of the nearly 800 
compounds reported from marine cyanobacteria, almost half correspond to the order 
Oscillatoriales where the genus Moorea (formerly Lyngbya, Engene et al., 2012) is the 
most prolific, followed by the genera Oscillatoria and Symploca (Figure 3) (Gerwick et al., 
2008). Studies of this subject have been mainly focused on the more complex species 
such as the filamentous forms that grow in high densities in the tropical and subtropical 
regions, thus being easily collected and cultured in large quantities, yielding enough 
biomass for chemical investigations (Schlegel et al., 1999). On the other hand, many 
marine cyanobacterial genera, namely unicellular free-living forms have been largely 
overlooked. Their existence in lower densities in the environment turns their collection and 
isolation processes more difficult, making it necessary to culture large amounts of 
Anti-inflamatory activity
Antifungal
Cytotoxicity
Antibiotic
Cytotoxicity against
cancer cell lines
No activity
Other
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biomass in the laboratory to proceed to the chemical investigations (Leão et al., 2013). 
The fact that filamentous and colonial forms appear to have larger genomes than the 
unicellular free-living ones, thus better accommodating polyketide (PKS) and non-
ribosomal peptide (NPKS) pathways, is another reason as why these complex species 
have been the major source of a variety of bioactive compounds (Shih et al., 2013).  
The biosynthetic pathways for these compounds are a widely studied topic. So far 
the majority of these compounds appear to be synthesized by NRPS or NRPS/PKS hybrid 
pathways (Welker & Dohren, 2006), pathways that lead to the production of a wide 
diversity of metabolites (Nunnery et al., 2010).  
Cyanobium, Synechocystis and Synechococcus are some examples of 
underexplored unicellular free-living genera of cyanobacteria. Given the importance of 
marine cyanobacteria as potential producers of bioactive compounds and the extensive 
coastal area of Portugal, studies with the goal of isolating new strains from these regions 
and their characterization, from an ecotoxicological and pharmacological point of view 
were performed, in order to evaluate their potential impacts on ecosystems and public 
health. Since then, several strains, including some of these genera have been maintained 
in the LEGE (Laboratory of Ecotoxicology, Genomics and Evolution) cyanobacteria culture 
collection at CIIMAR (Interdisciplinary Centre of Marine and Environmental Research). 
Recently, a study performed by Costa et al., (2014) revealed, through cytotoxicity assays 
of some unicellular free-living genera extracts against human cancer cell lines, that 
several strains had the potential for the isolation of secondary bioactive compounds. This 
happened for the compound hierridin B, which was isolated from the Cyanobium strain 
LEGE 06113, and exhibited selective cytotoxicity towards the colon adenocarcinoma cell 
line HT29 (Leão et al., 2013). 
Tan (2007), performed a revision work about 128 compounds isolated from marine 
cyanobacteria and determined that in more than 35% of them, cytotoxic ity against cancer 
cell lines was detected. Shown in Table 2 are some other marine cyanobacterial 
compounds with potential anticancer properties. 
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Figure 3 – Marine cyanobacteria from the order Oscillatoriales  indicating the major species 
that produce secondary bioactive compounds (Gerwick et al., 2008). 
. 
The fact that cyanobacterial compounds have revealed a large variety of structures 
and activities, has led to the creation of synthetic analogues with improved 
pharmacological and pharmacokinetic properties. Curacin A and Dolastatin 10 are some 
examples of molecules that have been in pre clinical or clinical trials as potential 
anticancer drugs (Gerwick et al., 2001). From Dolastatin 10, the analogues TZT-1027, 
ILX-651 were synthesized (Mita et al., 2006; Watanabe et al., 2006). TZT-1027 (or 
soblitodin), designed to have increased antitumor activity and reduced side effects, 
revealed to be superior to former existing anticancer drugs and underwent phase I testing 
for the treatment of solid tumors (Watanabe et al., 2006), while the antitumor agent ILX-
651 (or tasidotin), after its successful run in phase I trials, underwent into phase II trials 
(Mita et al., 2006). Brentuximab vedotin is the most recent anticancer agent from the 
marine environment. It was synthesized from monomethyl auristatin E, a dolastatin 10 
analogue, and is an extremely effective and well tolerated agent in the treatment of 
Hodgkin lymphoma and systemic anaplastic large-cell lymphoma (de Claro et al., 2012).  
 
Table 2 – Marine cyanobacterial compounds with potential anticancer properties. Adapted 
from Costa et al., 2012. 
Compound Source 
Class of 
compound 
Anticancer activity Reference 
Ankaraholide A Geitlerinema 
Glycosilated 
swinholide 
Cytotoxicity against 
NCI-H460 and MDA-
MB-435 cell lines 
(Andrianasolo 
et al., 2005) 
Apratoxins Lyngbya 
Cyclic 
depsipeptide 
Cytotoxicity against a 
panel of cancer cell 
lines 
(Luesch et al., 
2001,2002) 
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Aurilides 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Cytotoxicity against 
NCI-460 and neuro-
2a mouse 
neuroblastoma cells 
(Han et al., 
2006) 
Belamide A Symploca sp. 
Linear 
tetrapeptide 
Cytotoxicity against 
HCT-116 colon 
cancer line 
(Simmons et 
al., 2006) 
Bisebromoamide Lyngbya sp. Peptide 
Cytotoxicity against a 
panel of cancer cell 
lines 
(Teruya et al., 
2009a) 
Biselyngbyaside Lyngbya sp. Glicomacrolide 
Cytotoxicity against a 
panel of cancer cell 
lines 
(Teruya et al., 
2009b) 
Calothrixins Calothrix 
Pentacyclic 
indolophenan- 
thridine 
Bioactive against 
human HeLa cancer 
cells and apoptotic 
against human Jurkat 
cancer cells 
(Chen et al., 
2003) 
Caylobolide A 
Lyngbya 
majuscula 
Macrolactone 
Cytotoxicity against a 
panel of cancer cell 
lines 
(Macmilliam et 
al., 2003) 
Coibamide A 
Leptolyngbya 
sp. 
Cyclic 
depsipeptide 
Cytotoxicity against 
NCI-H460 and mouse 
neuro-2a cells 
(Medina et al., 
2008) 
Cryptophycin 1 Nostoc spp. 
Cyclic 
depsipeptide 
Cytotoxic activity in in 
vitro human tumor 
cell models 
(Wagner et 
al., 1999) 
Dolastatin 10 Symploca sp. 
Linear 
pentapeptide 
Cytotoxicity against 
four small-cell lung 
cancer (SCLS) lines 
(Kalemkerian 
et al., 1999) 
Ethyl tumonoate 
A 
Oscillatoria 
margaritifera 
Peptide 
Toxicity against H-
460 human lung 
tumor cells 
(Engene et 
al., 2011) 
Hoiamides 
Assemblage 
of Lyngbya 
majuscula and 
Phormidium 
gracile 
Cyclic 
depsipeptide 
Cytotoxicity against 
H460 human lung 
tumor cells 
(Choi et al., 
2010) 
Homodolastatin 
16 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Activity against 
esophageal and 
cervical cancer cell 
lines 
(Davies-
Coleman et 
al., 2003) 
Isomalyngamide 
Lyngbya 
majuscula 
Fatty acid 
amides 
Activity against tumor 
cell migration through 
the 1 integrin-
mediated 
antimetastatic 
(Chang et al., 
2011) 
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pathway 
Jamaicamides 
Lyngbya 
majuscula 
Polyketide-
Peptides 
Cytotoxicity against 
H460 human lung 
cancer and mouse 
neuro-2a cells 
(Edwards et 
al., 2004) 
Kalkitoxin 
Lyngbya 
majuscula 
Lipopeptide 
Cytotoxicity against  
human colon cell line 
HCT-116 
(White et al., 
2004) 
Lagunamides 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Cytotoxicity against a 
panel of cancer cell 
lines 
(Tripathi et al., 
2012) 
Largazole Symploca sp. 
Cyclic 
depsipeptide 
Anti-proliferative 
activity 
(Zeng et al., 
2010) 
Lyngbyabellin A 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Cytotoxicity against 
KB nasopharyngeal 
carcinoma and LoVo 
colon 
adenocarcinoma cells 
(Luesch et al., 
2000) 
Lyngbyaloside Lyngbya sp. Glicomacrolide 
Cytotoxicity against 
KB and LoVo cells 
(Luesch et al., 
2002) 
Majusculamide C 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Induction of 
filamentous F-actin 
loss against a10 cells 
(Pettit et al., 
2008) 
Malevamide D 
Symploca 
hydnoides 
Peptide ester 
Toxicity against 
AS49, HT29, MEL28 
and P388 cell lines 
(Horgen et al., 
2002) 
Malyngamides Lyngbya 
Fatty acid 
amines 
Cytotoxicity against 
NCI-H460 and neuro-
2a cancer lines 
(Gross et al., 
2010) 
Malyngolide 
dimmer 
Lyngbya 
majuscula 
Cyclodepside 
Toxicity against H460 
human lung cancer 
cell line 
(Gutierrez et 
al., 2010) 
Obyanamide 
Lyngbya 
confervoides 
Cyclic 
depsipeptide 
Cytotoxic against KB 
and LoVo cancer cell 
lines 
(Williams et 
al., 2002a) 
Palauamide Lyngbya sp. 
Cyclic 
depsipeptide 
Cytotoxic against KB 
oral epidermoid 
cancer 
(Zou et al., 
2005) 
Palmyramide A 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Blocking of sodium 
channels in neuro-2a 
cells and cytotoxicity 
against H460 human 
lung cancer cells 
(Taniguchi et 
al., 2010) 
Pitipeptolides 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Cytotoxicity against 
HT29 colon 
adenocarcinoma and 
(Montaser et 
al., 2011a) 
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MCF7 breast cancer 
cell lines 
Pitiprolamide 
Lyngbya 
majuscula 
Cyclic 
depsipeptide 
Cytotoxicity against 
HCT116 colon and 
MCF7 breast cancer 
cell lines 
(Montaser et 
al., 2011b) 
Somocystinamide 
A 
Lyngbya 
majuscula 
Lipopeptide 
Stimulates apoptosis 
in a number of tumor 
cell lines 
(Wrasidlo et 
al., 2008) 
Symplostatin 1 
Symploca 
hydnoides 
Linear 
pentapeptide 
Cytotoxicity against 
NCI-H460 and 
neuroblastoma cells 
(Mooberry et 
al., 2003) 
Tasiamide Symploca sp. Cyclic peptide 
Cytotoxicity against 
KB and LoVo cells 
(Williams et 
al., 2002b) 
Tasipeptins Symploca sp. 
Cyclic 
depsipeptide 
Cytotoxicity against 
KB cells 
(Williams et 
al.,2003a) 
Ulongapeptin Lyngbya sp. 
Cyclic 
depsipeptide 
Cytotoxicity against 
KB cells 
(Williams et 
al.,2003b) 
Veraguamides 
Symploca cf. 
hydnoides 
Cyclic 
depsipeptide 
Cytotoxicity against 
H460 human lung 
cancer cell line 
(Mevers et al., 
2011) 
Wewakazole 
Lyngbya 
sordida 
Cyclic 
dodecapeptide 
Cytotoxicity against 
H460 human lung 
cancer cell line 
(Malloy et al., 
2011) 
Wewakpeptins 
Lyngbya 
semiplena 
Depsipeptides 
Cytotoxicity against 
NCI-H460 human 
lung tumor and 
neuro-2a mouse 
neuroblastoma cell 
lines 
(Han et al., 
2005) 
 
1.3 Methodology used to detect and isolate new compounds 
 
Improvements in several approaches and strategies linking natural products with 
modern biology and screening platforms have been performed. The quality and amount of 
materials being studied in biological assays has been largely enhanced by automated 
extraction protocols joined with prefractionation strategies (Teruya et al., 2009b; 
Thornburg et al., 2011). The prefractionation of the extracts to lower complex mixtures or 
to single compounds enhances the success rates, due to the concentration of low 
abundance activities and speeds the identification process of the active compound. A 
fusion approach is usually performed, where extracts or fractions are tested for bioactive 
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agents, and if a significant activity is detected, then bioassay-guided techniques are used 
alongside with HPLC to fractionate and purify compounds while 1H-NMR and LC-MS are 
used to analyze the chemical constituents (Gerwick and Moore, 2012). 
 
1.3.1 Nuclear Magnetic Resonance Spectroscopy 
  
Nuclear magnetic resonance spectroscopy is an extremely important and vastly 
used method for structure elucidation of new metabolites.  
Several kinds of atomic nuclei act as if they were spinning around an axis. As they 
are positively charged, these spinning nuclei behave like small bar magnets and interact 
with an external magnetic field. This happens for both the proton (
1
H) and the 
13
C nucleus. 
When a proton is submitted to an external magnetic field, its angular momentum (or spin), 
will align itself by one of two ways: with the external magnetic field (parallel to) or against it 
(antiparallel to) (McMurry, 2007). Electromagnetic radiation can induce the proton to flip 
from one energy stage to another, leading the nucleus into a resonance stage. 
Resonance is the absorption of a certain frequency that will lead the nucleus of an atom to 
inverse its angular moment.  However, once a magnetic field is applied, the electrons 
surrounding the nucleus create small and local magnetic fields that will be opposite to the 
external field. This shows that the effective field to which the nucleus is subjected is 
smaller than the applied one, because of the moving electrons generating a shield around 
it. This is called shielding, and, to achieve the particular value in which absorption occurs, 
a shielded proton requires a higher magnetic force than one without shielding (McMurry, 
2007). This means that this phenomenon can increase NMR absorption values. A delta 
scale () and a reference are used to improve the measure and to define the peak’s 
position. The tetrametil-silano (TMS) absorption signal represents 0,0 ppm and the 
distance between the NMR signal of a certain proton and the one emitted by the TMS is 
called the proton’s chemical shift (McMurry, 2007). Each nucleus present in a different 
environment has a distinctive shield, and, this way, the NMR analysis provides a spectrum 
representing the chemical shifts of each compound tested allowing its detailed 
characterization. 
 In the early stages of this work, to evaluate the separation procedure, the different 
NMR spectra were obtained for each fraction. When the compounds were pure, 1D and 
2D NMR were used to differentiate the compounds obtained and as a first step towards 
structure elucidation.   
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1.3.2 Liquid Chromatography - Mass Spectrometry 
 
LC-MS, like NMR is a widely used method for aiding in structural elucidation. In 
order to get identification of the bioactive compound, liquid chromatography can be 
followed by mass spectrometry (Harada et al., 2004). Mass spectrometry is a method 
used for measuring the mass (molecular weight) and can provide information about its 
structure by breaking the molecule into smaller fragments while measuring their masses 
(McMurray, 2007). A mass spectrometer is composed by three parts: an ionization source, 
a mass analyzer and the detector. They operate by converting the molecules to a charged 
state with the ionization source, with consequent analysis of ions or fragment ions 
produced during this process according to their mass to charge ratio (m/z) by the mass 
analyzer. The detector observes and counts the separated ions and records them as 
peaks at different m/z (McMurray, 2007). The data of the mass spectroscopy is given as a 
bar graph with masses on the x axis and relative abundance of ions of a certain mass on 
the y axis (McMurray, 2007). 
Different technologies are applicable for both ionization and ion analysis. 
Electrospray Ionization (ESI), the most widely used ion source for biological molecules 
was used in this work. 
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2. Objectives 
Results from a screening on the anticancer potential of marine cyanobacteria 
strains isolated from the Portuguese coast performed in LEGE at CIIMAR, revealed 
several strains that had cytotoxicity against human cancer cell lines (Costa et al., 2014). 
Following these results, Synechocystis salina LEGE 06099 was chosen as one of the 
strains used in this work as it appeared to be one of the most interesting strains for the 
isolation of bioactive compounds. The Unidentified Chroococcales strain LEGE 10410 
was also chosen for this work, mainly due to the fact that it represents a largely untapped 
genus, even though for this strain no previous studies on its bioactive properties had been 
performed.  
The main objectives of this work were to isolate new compounds, from the 
selected cyanobacteria strains based on a bioassay-guided fractionation with cancer cell 
lines, to characterize its structure and to estimate its anticancer potency (in vitro). 
For this purpose, wet chemistry extraction techniques and High Performance 
Liquid Chromatography (HPLC) were used to isolate the compounds, Nuclear Magnetic 
Resonance (NMR) and Liquid Chromatography – Mass Spectrometry (LC-MSn) were used 
for deriving structural information and the 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl 
tetrazolium bromide (MTT) assay was used to estimate the anticancer potency. 
Complementary bioactive potential was also investigated by enzymatic and antimicrobial 
assays. 
  
Tiago Afonso  2014 
13 
 
3. Materials and Methods 
 
3.1 Cyanobacterial strains 
 
Synechocystis salina LEGE 06099 was isolated from the Portuguese coast 
(Moledo do Minho) and a monocyanobacterial culture of this strain is maintained in the 
LEGE Culture Collection (Brito et al., 2012). Large-scale cultures of this strain were 
carried out for biomass production and subsequent chemical investigations. S. salina cells 
were grown in Z8 medium (Kotai, 1972), supplemented with 20 g L-1 NaCl. Cultures were 
maintained at 25 ºC, with a light intensity of approximately 30 μmol photons m -2 s-1 and 
with a light/dark cycle of 14:10h. Exponential growing cells were harvested by 
centrifugation, frozen at -20 ºC and freeze-dried. The lyophilized biomass was stored at -
20 ºC. The Unidentified Chroococcales strain LEGE 10410 was also isolated from the 
Portuguese Coast (Vila Nova de Mil Fontes) and like the previous strain is maintained in 
the LEGE culture collection. Large-scale cultures of this strain were performed for 
biomass production and subsequent chemical investigations. Unidentified Chroococcales 
LEGE 10410 cells were grown in MN medium (Ripka, 1988) under the light and 
temperature conditions described above, then harvested, processed and stored also as S. 
salina cells. 
 
3.2  DNA extraction, PCR, cloning and sequencing of LEGE 10410 
 
The LEGE 10410 strain was characterized by molecular analysis of the 16S rRNA 
gene. Total genomic DNA was extracted from frozen samples using the PurelinkTM 
Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA) following the protocol described 
for Gram-negative bacteria. The primers: CYA359F and 781R (Neilan et al., 1997) were 
used for amplifying the 16S rRNA gene. The PCR conditions were as follows: initial 
denaturation at 94ºC for 4 minutes, followed by 35 cycles of denaturation at 94ºC for 30 
seconds, annealing at 52ºC for 30 seconds and extension at 72 ºC for 80 seconds and a 
final extension step at 72ºC for 5 minutes. All PCR reactions were prepared in a volume of 
20.0 µL containing 1×PCR buffer, 2.5 mM MgCl2, 250.0 mM of each deoxynucleotide 
triphosphate, 10.0 pmol of each of the primers, 0.5 U of Taq DNA polymerase (Bioline, 
Luckenwalde, Germany) and 10 ng of template DNA. PCR products were separated by 
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electrophoresis on a 1.5% (w:v) agarose gel. The gels were stained with ethidium bromide 
and photographed under UV transillumination. 
Amplicons of the expected size (~400 bp) were purified using Cut&Spin, DNA Gel 
Extraction Columns (Grisp, Portugal), according to the manufacturer’s instructions. 
Purified PCR products were then cloned into pGEM®-T Easy vector (Promega, Madison, 
WI, USA), and transformed into OneShot® TOP10 chemically competent Escherichia coli 
cells (Invitrogen, Carlsbad, CA, USA) using standard procedures (Sambrook and Russell, 
2001) and following the manufacturer’s instructions. Plasmid DNA was isolated using the 
GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA) and sequenced 
(Macrogen, Inc, Seoul, Korea) using M13 primers. The 16S rRNA sequences were 
inspected for quality and aligned with Geneious 7.1.7 (Biomatters). After alignment, the 
sequences obtained were inserted in the BLASTn (Basic Local Alignment and Search 
Tool for nucleotide) database, which allowed inferring determining the genus of the strain. 
 
3.3 Extraction and bioassay-guided fractionation of S. salina LEGE 
06099 biomass 
 
Cyanobacterial crude extracts were performed with the lyophilized material 
previously obtained by employing an apparatus assembled as shown in Figure 4. A 
mixture of dichloromethane:methanol (2:1) was added to and immersed the biomass of S. 
salina LEGE 06099 (15.3 g, d.w.). This mixture was allowed to remain for one hour at 
room temperature, while stirring homogenizing the biomass with a spatula. At the end of 
this hour the vacuum was turned on as the solvent contents were poured into the Büchner 
funnel and the resulting liquid phase was collected in a round bottom (RB) flask. Before 
starting a new step in the extraction, the biomass that had been poured was retained in 
the cheese cloth and recovered for a new extraction. This process was repeated one 
more time under these conditions and then four times at approximately 40ºC with the use 
of a hotplate, for 20 minutes each, with constant stirring. Following extraction, the RB flask 
was removed from the assembly and the solvents were removed in a rotary evaporator. 
The content of the RB flask was then resuspended and transferred to a pre-weighed glass 
vial which was dried in vacuum to yield 2.6 g of crude extract. 
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Figure 4 – System assemblage for organic extraction. 
 
The crude extract was then subjected to normal phase (silica gel 60, 0.0015-0.040 
mm, Merck, KgaA, Damstadt, Germany) vacuum liquid chromatography (VLC) (Figure 2). 
A gradient of solvents from 9:1 hexanes:EtOAc to 100% EtOAc to 100% MeOH was used 
in this VLC (Table 3), so as to obtain fractions with increased polarity. 
 
Table 3 – Gradient used for the VLC fractionation. 
Fraction EtOAc (%) Hexane (%) MeOH (%) Volume 
A 10 90 - > 250 mL 
B 20 80 - 250 mL 
C 30 70 - 250 mL 
D 40 60 - 250 mL 
E 60 40 - 250 mL 
F 80 20 - 250 mL 
G 100 - - 250 mL 
H 75 - 25 250 mL 
Hx 75 - 25 250 mL 
I - - 100 250 mL 
 
The crude extract was dissolved in the same percentage of solvents used for 
fraction A with the help of ultrasounds and loaded onto Whatman No1 filter paper placed 
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on top of the silica column and the solvent mixtures were added stepwise, according to 
Table 3, without allowing the silica surface to become dry and resulting in ten fractions (A 
– I) that were collected separately in RB flasks. The fractions were dried under reduced 
pressure, resuspended, transferred to pre-weighed vials and weighed before being 
inspected by 
1
H NMR (400 MHz, BrukerAvance III) and submitted to biological assays. 
 
 
Figure 5 – Apparatus for the vacuum liquid chromatography (VLC). 
 
Fraction F (196.2 mg), eluting with 80% EtOAc, was selected for further 
fractionation on the basis of its MTT cytotoxicity assay and because it had the highest 
mass. This was performed by a normal phase column chromatography (silica gel 60, 
0.040-0.063 mm, Merck, KgaA, Damstadt, Germany). 
A gradient of solvents from 30% EtOAc to 100% EtOAc to 25% MeOH was used 
for this fractionation (Table 4).  
Glass filtration funnel, fritted, 
porosity 3, 500 mL 
Whatman No1 filter paper 
Silica gel 60, 0.0015-0.040 mm 
Vacuum adapter 
Vacuum pump 
RB flask 
Braquet 
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Table 4 – Gradient used for the normal phase gravity column chromatography of fraction F. 
Collection tubes (%) EtOAc (%) Hexane (%) MeOH Volume 
1 – 3 30 70 - 200 mL 
4 – 27 
40 60 - 200 mL 
40 60 - 200 mL 
40 60 - 200 mL 
28 – 33 80 20 - 80 mL 
34 – 38 100 - - 80 mL 
39 – 44 75 - 25 80 mL 
 
Fraction F was dissolved in 30% EtOAc (Hexane) and loaded onto the silica 
column, which was assembled as shown in Figure 6. This chromatography was performed 
by gravity and 44 fractions were collected. 
 
      
Figure 6 – System assemblage for the normal phase column chromatography of fraction F.  
 
The fractions were inspected by thin-layer chromatography (TLC) and pooled in 
RB flasks according to their TLC profile (Table 5). The TLC was performed in a container 
with a 10 mL solution of 50% EtOAc and 50% Hexane. Each of the collection tubes were 
Chromatography column 
Silica gel 60, 0.040-0.063 mm 
Sand 
Cotton ball 
Collection tube 
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spotted onto the TLC plate which was visualized under UV light and with PMA 
(Phosphomolybdic acid) stain. 
 
Table 5 – Fraction pooling after TLC. 
 
 
 
The pooled fractions in RB flasks were dried on rotary evaporator, resuspended 
and transferred to pre-weighed glass vials. After solvent removal in vacuum each of the 
twelve sub-fractions (F-1 to F-12) was weighed, inspected by 1H NMR (400 MHz, 
BrukerAvance III) and submitted to a cytotoxicity assay. 
 
3.4 Semi-preparative HPLC conditions 
 
After analyzing the 1H NMR and the cytotoxicity assays, several fractions were 
selected for further purification by semi-preparative HPLC on the basis of its MTT 
cytotoxicity assay. A 1525 Binary HPLC pump and a 996 PDA detector (Waters, Milford, 
MA, USA) were used in all semi-preparative separations. Each fraction had to undergo a 
process of optimization whereby different gradients were tested until the best possible 
separation was achieved. The conditions for the optimized separation of the components 
of each sub fraction are described below. The peaks shown in the chromatograms were 
collected in RB flasks from multiple injections and the solvents removed in vacuo before 
being resuspended and transferred to pre-weighed vials. The HPLC fractions were 
Collection Tubes Fraction 
1 – 2 F-1 
3 – 4 F-2 
5 – 6 F-3 
7 – 11 F-4 
12 – 13 F-5 
14 – 15 F-6 
16 F-7 
17 – 23 F-8 
24 – 28 F-9 
29 – 32 F-10 
33 – 41 F-11 
42 – 44 F-12 
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weighed and then inspected by 1H NMR (400 MHz, BrukerAvance III) and submitted to a 
cytotoxicity assay. 
 
3.4.1. Sub-fraction F-5  
 
The separation of sub-fraction F-5 was carried out with a Synergi Fusion-RP 
column (10 m, 250 x 10 mm, Phenomenex, Torrance, CA, USA) by employing the 
gradient program described in Table 6. 
 
Table 6 – Mobile phase gradient used for the semi-preparative HPLC on sub-fraction F-5. 
Time Flow (mL/min) MeCN (%) H2O (%) 
0 3 87 13 
40 3 87 13 
45 3 100 0 
52 3 100 0 
55 3 87 13 
60 3 87 13 
 
3.4.2. Sub-fraction F-6 
 
The chromatographic system used for the semi-preparative RP-HPLC of the sub-
fraction F-6 was the same that was used for sub-fraction F-5. The gradient program used 
for the separation of this sub-fraction is shown in Table 7. 
 
Table 7 – Mobile phase gradient used for the semi-preparative HPLC on sub-fraction F-6. 
Time Flow (mL/min) MeCN (%) H2O (%) 
0 3 85 15 
25 3 100 0 
60 3 100 0 
70 3 85 15 
75 3 85 15 
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After the HPLC, the collected samples were subjected to 1H NMR and a 
cytotoxicity assay. Fractions F-6.2 and F-6.3 were found to require a new round of 
purification using analytical-scale HPLC. 
 
3.4.3. Sub-fraction F-6.2 
 
The chromatographic system used for the analytical-scale RP-HPLC purification of 
sub fraction F-6.2 was fitted with a Synergi Fusion-RP column (4 m, 250 x 4.60 mm, 
Phenomenex, Torrance, CA, USA). The gradient program used for the separation of this 
fraction is shown in Table 8. 
 
Table 8 – Mobile phase gradient used for the analytical-scale HPLC on sub-fraction F-6.2. 
Time Flow (mL/min) MeCN (%) H2O (%) 
0 1 70 30 
43 1 70 30 
45 1 99 1 
60 1 99 1 
 
 
3.4.4 Sub-fraction F-6.3 
 
The chromatographic system used for the analytical-scale RP-HPLC of the sub 
fraction F-6.3 was the same used for the sub fraction F-6.2. For this separation an 
isocratic program of 73% MeCN (aq) was employed. 
 
3.4.5 Sub-fraction F-7 
 
The chromatographic system used for the semi-preparative RP-HPLC of the sub 
fraction F-7 was the same used for the sub fraction F-6. The gradient program used was 
also the same.  
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3.5 Extraction and fractionation of Uncultured Chroococcales strain 
LEGE 10410 
 
Cyanobacterial crude extracts were performed with the lyophilized material 
obtained by employing an apparatus, identical to the one described for S. salina LEGE 
06099. The mixture of dichloromethane:methanol (2:1) was added to and immersed the 
biomass of Uncultured Chroococcales strain LEGE 10410 (14.2 g, d.w.). The first two 
steps were carried out for 1 hour at room temperature. It was visible that few pigments 
were being extracted, an indication of poor solvent penetration in the cells due to the 
exopolyssacharide matrix, so, for the next step in the extraction, along with heat 
(approximately 40º C), ultrasounds were also used. Three steps of 20 minutes each were 
performed under these conditions. Still, very low pigment extraction was visible, so 
sonication was used 20 times for 30 seconds with a 30 second interval between each use. 
Despite these conditions, it was still difficult to extract mass from this cyanobacterial 
strain. For that reason the biomass was left with a solution of dichloromethane:methanol 
(2:1) over the 48 hours with constant stirring. After the weekend, two more steps (similar 
to the previously done with the use of the sonicator) were performed. As no more 
pigments were being extracted, the extraction was concluded. The RB flask was removed 
from the assembly and the solvents were removed under reduced pressure. The contents 
of the RB flask were then resuspended and transferred to a pre-weighed glass vial, which 
was dried in vacuo to yield 0.6 g of crude extract.   
The VLC for this strain had the same conditions used for the VLC of S. salina 
LEGE 06099, except it wasn’t required the collection of the fraction Hx.    
The fractions obtained were then inspected by 1H NMR (400 MHz, BrukerAvance 
III) and submitted to cytotoxic and enzymatic assays. 
 
3.6 LC-HR-ESI-MS analysis 
 
For the mass spectrometry analysis, samples were taken to Centro de Materiais 
da Universidade do Porto (CEMUP) for analysis. It was used an HPLC Accela with Accela 
PDA detector, Accela Autosampler and Accela 600 Pump (Thermo Fischer Scientific, 
Bremen, Germany) to perform the chromatographic separation. The utilized instrument 
was a LTQ Orbitrap XL mass spectrometer (Thermo Fischer Scientific, Bremen, 
Germany) controlled by LTQ Tune Plus 2.5.5 and Xcalibur 2.1.0. 
Tiago Afonso  2014 
22 
 
The capillary voltage of the electrospray ionization (ESI) was set to 2800 V. The 
capillary temperature was 300ºC. The sheath gas and auxiliary gas flow rate (nitrogen) 
were set to 40 and 10 (arbitrary unit as provided by the software settings). The capillary 
voltage was -48 V and the tube lens voltage -247.79V. The volume of each injection was 
20L at approximately 50 g mL-1 and the gradient program used for all samples were as 
indicated in Table 9. 
 
Table 9 - Mobile phase gradient used for the chromatographic separation of all tested 
samples. 
Time (min) H2O (%) MeCN (%) Flow ( µL/mL) 
0 13 87 500 
25 13 87 500 
30 0 100 500 
35 0 100 500 
36 13 87 500 
40 13 87 500 
 
3.7 NMR analysis 
 
For the nuclear magnetic resonance (NMR), samples were prepared in the 
laboratory in specific NMR tubes (Norell Standard SeriesTM 5mm NMR tubes, Sigma-
Aldrich) with CDCl3 or DMSO-d6 and taken to CEMUP for analysis at 400 MHz 
(BrukerAvance III) or 600 MHz (BrukerAvance III equipped with a CryoProbeTM Prodigy). 
 
3.8 Cell lines and cytoxicity assays 
 
All the cell lines included in this study are of human origin. Cytotoxic assays were 
performed with the cell lines T47D (breast carcinoma cells), RKO (colon carcinoma cells) 
and MG63 (osteosarcoma cells). Cell lines were selected according to previous studies 
(Costa et al., 2014). Tumor cells were cultured in DMEM Glutamax medium (Dulbecco’s 
modified Eagle Medium DMEM GlutaMAXTM – Gibco-Invitrogen), supplemented with 10% 
(v/v) fetal bovine serum (Gibco-Invitrogen), 5 mL fungizone (2.5 μg mL−1) (Gibco-
Invitrogen) and 5 mL of penicillin-streptomycin (Pen-Strep 100 IU mL-1 and 10 mg mL-1, 
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respectively) (Gibco-Invitrogen). Cells were incubated in a humidified atmosphere with 5% 
of CO2, at 37ºC. 
The cellular viability was evaluated by the reduction of the 3- (4.5 dimethylthiazole-
2-yl)-2.5-diphenyltetrazolium bromide (MTT) (Alley et al., 1988) a yellow tretazole soluble 
in water, to purple formazan crystals that are insoluble in water. The reduction of MTT to 
formazan is directly proportional to the mitochondrial activity and consequently cell 
viability. 
 Cells were seeded in 96-well culture plates at a concentration of 3.3 x 10
4
 cells 
cm-2. After 24 hours of adhesion, cells were exposed to 100 L fresh medium 
supplemented with the compounds to a final concentration of 3 and 30 g mL-1 for a 
period of both 24 and 48 hours. After incubation cells were exposed to 10 L of 0.5 mg 
mL
-1
 MTT. Following exposure, the purple-colored formazan salts were dissolved in 100 
L DMSO and the absorbance measured at 550 nm in a microplate reader (Synergy HT, 
Biotek, USA). All tests were run in triplicate and averaged. A similar procedure was 
undertaken for determining the IC50 value of the compounds in the T47D, RKO and MG63 
cell lines. In this case, however, cells were incubated for 48 hours and the final 
concentrations of the compounds ranged from 0.003 to 50 g mL-1. Dose-response data 
was used to calculate the IC50 with the software GraphPad Prism v6.0 (GraphPad 
Software, La Jolla, CA, USA). 
 
3.9 Enzymatic assays 
 
3.9.1 HDAC assay 
The HDAC-Glo™ I/II assay activity assay and screening system (Promega) was 
used to evaluate the relative activity of histone deacetylase (HDAC) class I and II 
enzymes. The assay was performed as indicated in the manufacturer’s protocol. Briefly, 
the HDAC-Glo™ I/II Reagent was prepared by adding buffer and developer enzyme to 
lyophilized luciferase reaction components. Diluted HeLa nuclear extract and the inhibitor 
trichostatin A were prepared by adding buffer to stock solutions respectively. Then, the 
Reagent was added to the HeLa nuclear extract (HDAC enzyme source) with or without 
inhibitor. The tests were performed in 96-well white-walled plates with a final volume of 
200 L and the extracts were tested at 3 g mL-1. The plates were incubated at room 
temperature for 30 minutes, after which the luminescent signal was measured in a 
microplate reader (Synergy HT, Biotek, USA). 
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3.9.2 Proteasome assay 
The Proteasome-Glo™ Chymotrypsin-Like Cell-Based Assay (Promega) was used 
in addition to the Trypsin-Like and Caspase-Like Assays to evaluate the three major 
proteolytic activities. The assays were performed as indicated in the manufacturer’s 
protocol. Briefly, the Proteasome-Glo™ Substrate was prepared by adding buffer and 
substrate Suc-LLVY-Glo™ for the Chymotrypsin-Like Assay, Z-LRR-Glo™ substrate for 
the Trypsin-Like Assay and Z-nLPnLD-Glo™ substrate for the Caspase-Like Assay. The 
Proteasome-Glo™ Reagent was prepared by adding the Proteasome-Glo™ Substrate to 
the Luciferin Detection Reagent and it was left to incubate for 60 minutes. The 20S 
proteasome enzyme and the inhibitor epoxomicin were also prepared by adding buffer to 
stock solutions. The tests were performed in 96-well white-walled plates with a final 
volume of 100 L and the extracts were tested at 3 g mL-1. The plates were incubated at 
room temperature for 30 minutes, after which the luminescent signal was measured in a 
microplate reader (Synergy HT, Biotek, USA). 
 
3.10 Antimicrobial screening susceptibility assay 
 
For the antimicrobial screening susceptibility assay two Gram-positive bacterial 
strains (Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 6633) and two 
Gram-negative bacterial strains (Escherichia coli ATCC 25922 and Pseudomonas 
aeruginosa ATCC 27853) were used as well as a species of yeast (Candida albicans). 
These bacteria were grown in Mueller-Hinton agar (MH – BioKar diagnostics, France) 
from stock cultures. MH plates were initially incubated at 37ºC so as to obtain fresh 
cultures for each in vitro bioassay. The disc diffusion method on MH was used. Briefly, 
bacterial pure colonies were picked from overnight cultures in MH and suspended in 5 mL 
of buffered peptone water (Oxoid, England). MH plates were seeded with that inoculum. 
Blank discs (6 mm in diameter, Oxoid, England) were placed in the inoculated plates and 
then, impregnated with 15 L of a 1 mg mL-1 solution (in DMSO) of each test compound 
(DMSO was used as a negative control). Plates were incubated overnight at 37ºC and 
antimicrobial activity was recorded when a halo around the disc was visible.  
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4. Results and Discussion 
 
4.1  Extraction and bioassay-guided fractionation of S. salina 
biomass. 
 
From 15.3 g, d.w. of S. salina biomass, a 17.0% yield (2.6 g) of crude extract was 
obtained (extraction code E13010). This crude extract was then submitted to a normal 
phase liquid chromatography resulting in ten fractions (A – I). The MTT assay was used to 
evaluate the effects of the different fractions obtained on the inhibition of cellular 
proliferation of human cancer cell lines, as this is a fast colorimetric method frequently 
used to measure cell proliferation and cytotoxicity (Berridge & Tan, 1993). The MTT is 
accumulated by the cells by endocytosis and the reduction of the tetrazole ring in this salt 
results in the formation of purple formazan crystals, which accumulate in endosomal 
and/or lysosomal compartments, being later transported out of the cell by exocytosis. Due 
to the fact that this a fundamental mechanism of living cells, this assay has been 
frequently used to determine cellular viability.  
To perform the MTT assay, three cancer cell lines were used, RKO, MG63 and 
T47D. Fractions for which a decrease in cellular viability was in the range of 90-80% were 
selected for follow-up studies. 
The results regarding cell viability of the RKO, MG63 and T47D cell lines exposed 
to E13010 crude extract and E13010 VLC fractions, with a concentration of 100 g mL-1 
and 10 g mL-1 in 96 well plates, revealed that fraction F, G and H inhibited cell viability at 
the end of both test times (24 and 48 hours) for the highest concentration. The lowest 
concentration tested showed no cellular inhibition (Figure 7).  
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Figure 7 – Cell viability (% of negative control) from E13010 crude extract and VLC 
fractions (A – I) with the concentration of 100 g mL
-1
(*) and 10 g mL
-1
 on the RKO (a), MG63 (b) 
and T47D (c) cancer cell lines, with two exposure times, 24H and 48H at 3.3 x 10
4
 cells per well. 
Negative control corresponded to 1% DMSO and positive control to 20% DMSO.  
 
For the enzymatic and antimicrobial susceptibility assays, no activity was detected 
for these fractions. 
From these results, fraction F was selected for further purification as it was the 
bioactive fraction with higher mass (196.2 mg), thus increasing the possibility of isolating 
compounds with enough mass for the chemical investigations. This fraction was then 
subjected to a normal phase column chromatography and the resulting sub-fractions were 
tested for cytotoxicity at a concentration of 30 and 3 g mL-1 on the MTT assay (see 
Appendix I, Figure 1). The results obtained from the assay revealed that bioactivity of 
fraction F was located in the resulting fractions E13010 F-5 (96.0 mg) and F-6 (40.3 mg). 
Following the bioactivity and analyzing the 1H NMR of these fractions, they were selected 
for further purification by semi-preparative HPLC. 
Semi-preparative HPLC of sub-fraction F-5 followed the gradient program 
described in Table 5 and the resulting chromatogram is shown is Figure 8. From this 
HPLC, ten sub-fractions were collected (E13010 F-5.1 to F-5.10) corresponding to single 
peaks or clusters of peaks, which were then subjected to the MTT assay. 
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Figure 8 – Chromatogram of E13010 F-5 showing highlighted sub-fraction F-5.4. 
Conditions of the injection were as followed: 100 L at a concentration of ~19 mg mL
-1
. 
 
Sub-fraction E13010 F-5.4 corresponds to the peak highlighted in Figure 8. 
Through the MTT assay, this sub-fraction revealed to highly decrease cellular viability for 
all  the three cancer cell lines tested, thus showing that the bioactivity of fraction F-5 was 
located in this sub-fraction (see Appendix I, Figure 2). For the gradient program and 
conditions used, the retention time of this peak was of approximately 26.5 minutes. The 
visible peak was not collected entirely due to visible overlapping of different peaks around 
minutes 29 and 31. After all 96 mg of fraction F-5 had been subjected to semi-preparative 
HPLC, 30.4 mg of sub-fraction F-5.4 were collected. Analysis of the 1H NMR of this sub-
fraction revealed a pure compound that was selected for NMR-based characterization. 
Semi-preparative HPLC of sub-fraction F-6 followed the gradient program 
described in Table 6 and twelve sub-fractions (F-6.1 to F-6.12) were collected from single 
peaks or clusters of peaks. The MTT assay revealed that sub-fractions E13010 F-6.2, F-
6.3 and F-6.4 (respectively 1, 2 and 3 in Figure 9) decreased cellular viability for all three 
cancer cell lines (see Appendix I, Figure 3). After all 40.3 mg of fraction F-6 had been 
subjected to semi-preparative HPLC, 0.9 mg, 1.2 mg and 12.8 mg of sub-fractions F-6.2, 
F-6.3 and F-6.4 respectively, were collected. Analysis of the 1H NMR of sub-fractions F-
6.2 and F.6.3 revealed the need to perform another round of purification using analytical-
scale HPLC. Sub-fraction F-6.4 (RT of approximately 20.5 minutes) revealed a pure 
compound and was selected for NMR-based characterization. 
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Figure 9 – Chromatogram of E13010 F-6 showing highlighted sub-fraction F-6.2 (1); F-6.3 
(2) and F-6.4 (3). Conditions of the injection were as followed: 200 L at a concentration of ~8 mg 
mL
-1
. 
 
 
Figure 10 – Chromatogram of E13010 F-6.2 showing highlighted sub-fraction F-6.2.1. 
Conditions of the injection were as followed: 40 L at a concentration of ~1 mg mL
-1
. 
 
Analytical-scale HPLC of sub-fraction F-6.2 followed the conditions described in 
Table 8 and the chromatogram obtained is showed in Figure 10. Sub-fraction F-6.2.1, 
corresponding to the peak highlighted in Figure 10 with a retention time of approximately 
38 minutes was the major peak, yielding 0.5 mg. In the MTT assay of this sub-fraction, all 
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three cancer cell lines had their cellular viability decreased (see Appendix I, Figure 4). 
Analysis of the 1H NMR of this sub-fraction revealed a pure compound that was selected 
for NMR-based characterization. 
 
 
Figure 11 – Chromatogram of E13010 F-6.3 showing highlighted sub-fractions F-6.3.2 (1), 
F-6.3.3 (2) and F-6.3.8 (3). Conditions of the injection were as followed: 40 L at a concentration of 
~1 mg mL
-1
. 
 
Sub-fraction E13010 F-6.3 was submitted to analytical-scale HPLC, which followed 
the conditions described in the section 3.4.4. The chromatogram of this sub-fraction is 
shown in Figure 11. Through this chromatogram, 8 sub-fractions (F-6.3.1 to F-6.3.8) were 
collected and subjected to the MTT assay. Sub-fractions F-6.3.2 (highlighted as 1) and F-
6.3.3 (highlighted as 2) showed a decrease in cellular viability for all three cancer lines 
tested (see Appendix I, Figure 4). F-6.3.8 (highlighted as 3) didn’t show significant results 
in the MTT assay, but due to its 1H NMR spectrum it was selected for further 
characterization. For these reasons, sub-fractions F-6.3.2 (0.2 mg; RT=34.5 minutes), F-
6.3.3 (0.2 mg; RT=38 minutes) and F-6.3.8 (0.3 mg; RT=52.25 minutes) were selected for 
further characterization. 
Even though through the cytotoxicity assay, fraction F-7 (4.1 mg) didn’t reveal 
bioactivity, it was still submitted to a semi-preparative HPLC because it was the immediate 
fraction following the fractions containing bioactivity, and could still have some of the 
previous compounds in low quantities. The conditions of the HPLC were as described in 
section 3.4.5 and the resulting chromatogram is shown in Figure 12. This chromatogram 
was very similar to the one of fraction F-6.4 which was tested with the same gradient 
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program. The peak shown highlighted in Figure 5 was collected as sub-fraction F-7.4 (0.9 
mg; RT=20 minutes) and tested in the MTT assay. In the cytotoxicity assay this sub-
fraction didn’t reveal appreciable activity (see Appendix I, Figure 4) but the 1H NMR 
spectrum revealed a pure compound and so it was selected for NMR-based 
characterization. 
 
.  Figure 12 – Chromatogram of E13010 F-7 showing highlighted sub-fraction F-7.4. 
Conditions of the injection were as followed: 200 L at a concentration of ~4 mg mL
-1
. 
 
Concluding the isolation process of all these fractions/compounds, they were 
selected for Nuclear Magnetic Resonance and Liquid Chromatography – Mass 
Spectrometry analysis. Table 10 summarizes all the isolated fractions of interest. 
 
Table 10 – Compendium of all interesting isolated fractions for further chemical analysis 
and their respective obtained mass. 
Isolated Fractions Obtained Mass (mg) 
F-5.4 30.4 
F-6.4 12.8 
F-6.2.1 0.5 
F-6.3.2 0.2 
F-6.3.3 0.2 
F-6.3.8 0.3 
F-7.4 0.9 
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4.2 LC-HR-ESI-MS and NMR of the Fractions obtained. 
 
All fractions compiled in Table 9 were subjected to Mass Spectrometry analysis at 
CEMUP with the objective of deriving structural information of the present compounds. 
In Figure 13A are shown the liquid chromatography results for each fraction and 
for a pool of all fractions, evidencing differences and similarities between fractions. Figure 
13B shows the mass spectrum for each main peak present in the different fractions. 
Analysis of the NMR data obtained for each fraction/compound is also described in this 
section. 
 
4.2.1  Compound F-5.4 
 
 E13010 F-5.4, a pale yellow amorphous solid UV MeOH [absorption maxima at 
= 205 nm (log= 3.33), = 229 nm (log= 3.37), = 245 nm (log= 3.38), = 257 nm 
(log= 3.36)]; the HR-ESI-MS established an [M - H]- m/z 659.3838, calculated 659.3845 
for C36H61Cl2O6. In the conditions tested, this fraction presented a retention time of 10.33 
minutes. Comparing the LC-MS of F-5.4 and F-6.4 their retention times were very similar, 
10.33 and 10.26 minutes respectively. The mass spectrum for both was similar, and so 
were the NMR data, thus these two compounds are presumed to be equal. For this 
compound it was possible to obtain 1D 1H and 13C NMR spectra (Figure 14) and 2D 
HSQC, HMBC, COSY and NOESY NMR spectra (see Appendix II, Figure 1 and 2). 
Heteronuclear single quantum coherence (HSQC) provides one bond 1H-13C spectra while 
Heteronuclear multiple bond correlation (HMBC) provides an N-bond (n = 2 or 3) 1H-13C 
shift correlation spectra (Breton and Reynolds, 2013). Correlation spectroscopy (COSY) 
provides homonuclear 1H-1H correlation spectra and the Nuclear Overhauser effect 
spectroscopy (NOESY) identifies pairs of protons that are spatially close (Breton and 
Reynolds, 2013). 
 
Tiago Afonso  2014 
32 
 
A)
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Figure 13 – LC-MS analysis of all fractions obtained. Panel A) – Liquid Chromatography of 
all individual fractions and a pool of all fractions. Panel B) – Mass spectrum for each of the main 
chromatographic peaks of each fraction.  
600 650 700
m/z
0
50
100
0
50
100
0
50
100
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
0
50
100
0
50
100
0
50
100
659.3846
695.3611
722.3803
695.3603
659.3838
667.3285
631.3517
719.4036
683.4271
681.3446
645.3680
695.3598
722.3783659.3832
695.3602
659.3837
NL: 2.79E5
TiagoAfonso_CIIMAR_F7-
4_negative#657  RT: 10.40  AV: 1 SB: 
2  0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
NL: 5.15E5
TiagoAfonso_CIIMAR_F5-
4_negative#653  RT: 10.34  AV: 1 SB: 
2  0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
NL: 6.75E5
TiagoAfonso_CIIMAR_F6-2-
1_negative#474  RT: 7.50  AV: 1 SB: 2 
 0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
NL: 7.18E5
TiagoAfonso_CIIMAR_F6-3-
2_negative#545  RT: 8.62  AV: 1 SB: 2 
 0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
NL: 5.05E5
TiagoAfonso_CIIMAR_F6-3-
3_negative#554  RT: 8.76  AV: 1 SB: 2 
 0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
NL: 2.87E5
TiagoAfonso_CIIMAR_F6-3-
8_negative#655  RT: 10.37  AV: 1 SB: 
2  0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
NL: 5.91E5
TiagoAfonso_CIIMAR_F6-
4_negative#648  RT: 10.25  AV: 1 SB: 
2  0.03  , 0.03 F: FTMS - p ESI Full ms 
[200.00-3000.00] 
Tiago Afonso  2014 
34 
 
 
Figure 14 – 
1
H-NMR (A) and 
13
C-NMR (B) spectra of compound F-5.4/F-6.4 in CDCl3 
(recorded at 400 MHz). 
 
Structural elucidation of this compound is underway, but the first step has already 
been made by identifying some correlations obtained from HSQC and HMBC spectra for 
single and multiple bond correlations, respectively (Table 11), suggesting the presence of 
an aromatic ring from several 13C resonances between 155.61-107.27 and 1H 
resonances of 6.50-6.35  
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Table 11 – NMR spectroscopy data for F-5.4 in CDCl3 at 600 MHz. 
Number
a 
C  H (mult., J in Hz) HMBC 
1 155.61   
2 154.31   
3 142.28   
4 116.14   
5 110.36 6.35 (d, 1.1) C-2, C-3, C-4, C-6, C-16, C-30 
6 107.94 6.50 (d, 1.0) C-1, C-3, C-4, C-5, C-16, C-30 
7 101.27 5.01 (d, 6.1) C-1, C-8, C-10, C-13 
8 74.60 3.71 (m) C-7, C-10, C-13 
9 72.53 3.72 (m) C-8, C-10 
10 69.58 3.83 (m) C-8, C-9, C-14 
11 64.64   
12a 64.56 3.46 (d, 3.9) C-7, C-8, C-10 
12b  3.88 (m) C-14, C-28 
13 64.48 4.11 (dd, 4.3, 11.9)  
14 38.70   
15 38.63 1.69 (m)  
16 35.91 2.49 (m) C-3, C-5, C-6, C-19, C-21 
17 31.85 1.29 (m) C-30, C34 
18 31.52   
19 31.20 1.57 (m)  
20 29.80   
21 29.51 1.51 (m)  
22 29.31 1.34 (m)  
23 29.20   
24 29.17   
25 28.99   
26 26.61 1.51 (m)  
27 26.57   
28 26.56 1.40 (m)  
29 26.32 1.69 (m) C-27 
30 23.48 2.59 (m) C-1, C-2, C-4, C-20 
31a 22.73 1.30 (m)  
31b  0.89(t, 7.0)  
32 22.68   
33 14.20 0.89 (t, 7.0) C-17/19, C-32 
34 14.16 0.89(t, 7.0)  
a 
Numbering is for reference purposes, only. 
4.2.2  Compound F-6.2.1 
 
E13010 F-6.2.1, a colorless amorphous solid UV MeOH [absorption maxima at = 
205 nm (log= 3.81), = 229 nm (log= 3.86), = 245 nm (log= 3.87), = 257 nm 
(log= 3.85)]; the HR-ESI-MS established an [M - H]- m/z 631.3517, calculated 631.3532 
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for C34H57Cl2O6. In the conditions tested, this fraction presented a retention time of 7.49 
minutes (Figure 13A).  
In comparison with compound F-5.4, compound F-6.2.1 appears to have lost an 
ethylene equivalent (C2H4), which corresponds to the m/z 28.032 difference. For this 
compound it was possible to obtain 1D 
1
H and 
13
C NMR spectra (Figure 15) and 2D 
HSQC, HMBC and COSY NMR spectra (see Appendix II, Figure 3 and 4).  
 
 
  
Figure 15 – 
1
H-NMR (A) and 
13
C-NMR (B) spectra of compound F-6.2.1 in DMSO-d6 
(recorded at 600 MHz). 
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Structural elucidation of this compound is underway, but, like for compound F-5.4, 
the first step has already been made by identifying some correlations obtained from 
HSQC and HMBC spectra for single and multiple bond correlations, respectively (Table 
12). Like to the previous compound, these data suggest the presence of an aromatic ring 
from several 
13
C resonances between 156.18-106.15 and 1H resonances of 6.31-6.29
Table 12 – NMR spectroscopy data for F-6.2.1 in DMSO-d6 at 400 MHz. 
Number
a 
C   H (mult., J in Hz) HMBC 
  8.99 (s) C-2, C-4 
1 156.18   
2 155.56   
3 140.30   
4 115.81   
5 108.96 6.29 (d, 1.3) C-2, C-4, C-6, C-18 
6 106.15 6.31 (d, 1.3) C-1, C-4, C-5, C-18 
7 101.80 4.70 (d, 7,2) C-1 
8 76.59 3.20 (m)  
9 73.32 3.20 (m)  
10a 69.44 3.34 (m) C-9 
10b  3.51 (s)  
11a 65.63 3.71 (dd, 5.3, 11.3) C-10 
11b  3.16 (m)  
12 64.88 4.01 (m)  
13 64.79 4.01 (m)  
14a 37.88 1.72 (m)  
14b  1.62 (m)  
15 37.80   
16 37.78   
17 37.54 1.62 (m)  
18 35.15 2.40 (m) C-3, C-5, C-6, C-22/26, C-20 
19 30.73 1.23 (m)  
20 30.66 1.49 (m) C-18, C-24 
21 29.02   
22 28.75 1.40 (m)  
23 28.52   
24 28.46   
25 28.32   
26 28.11   
27 25.96   
28 25.84   
29 25.56   
30a 22.54 2.54 (m) C-2, C-4, C-22/26 
30b  2.46 (m) C-1, C-4, C-22/26 
31 21.88   
32 21.67   
33a 13.87 0.86 (t, 7.0) C-20, C-31 
33b  0.87 (t, 7.4) C-26, C-32 
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a 
Numbering is for reference purposes, only. 
4.2.3. Compound F-7.4 
  
E13010 F-7.4, a colorless amorphous solid UV MeOH [absorption maxima at = 
205 nm (log= 3.43), = 229 nm (log= 3.47), = 245 nm (log= 3.48), = 257 nm 
(log= 3.46)]; the HR-ESI-MS established an [M - H]- m/z 659.3838, calculated 659.3845 
for C36H61Cl2O6, same as F-5.4 and F-6.4, but further tests were necessary to confirm the 
hypothesis that it is the same compound. From Figure 13A, the retention time of this 
compound was of 10.40 minutes, again, very similar to F-5.4 (10.33 minutes). For this 
compound it was possible to obtain 1D 1H and 13C NMR spectra (Figure 16) and 2D 
HSQC, HMBC and COSY NMR spectra (see Appendix II, Figure 5 and 6). 
 
Figure 16 – 
1
H-NMR (A) and 
13
C-NMR (B) spectra of compound F-7.4 in DMSO-d6 
(recorded at 600 MHz). 
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Structural elucidation of this compound is underway and like for the previous 
compounds, correlations obtained from HSQC and HMBC spectra for single and multiple 
bond correlations, respectively, were established (Table 13). Comparing these data to the 
one obtained from the previous compound, compound F-7.3 shows a peak at C31.13 
which doesn’t appear in compound F-6.2.1, while everything else seems similar including 
the aromatic ring. These are clearly a family of related compounds, based on the similar 
NMR data, and, given the similar HR-MS data for some of the isolated metabolites, some 
should either be constitutional or stereoisomers.  
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Table 13 – NMR spectroscopy data for F-7.4 in DMSO-d6 at 400 MHz. 
Number
a 
C  H (mult., J in Hz) HMBC 
  8.99 (s) C-2, C-4 
1 156.17   
2 155.56   
3 140.29   
4 115.80   
5 108.96 6.29 (d, 1.1) C-2, C-4, C-6, C-18 
6 106.15 6.31 (d, 1.1) C-1, C-2, C-5, C-18 
7 101.79 4.70 (d, 7.2) C-1 
8 76.58 3.20 (m) C-9 
9 73.31 3.20 (m) C-7, C-8 
10 69.44 3.35 (m)  
11a 65.62 3.16 (m) C-7 
11b  3.72 (dd, 5.3,11.3) C-7, C-8, C-10 
12 64.88   
13 64.81 4.01 (m)  
14a 37.88 1.71 (m)  
14b  1.61 (m) C-13 
15 37.83   
16 37.79   
17 37.78   
18 35.15 2.40 (t, 7.5) C-3, C-5, C-6, C-23/27, C-21 
19 31.13   
20 30.73 1.24 (m)  
21 30.66 1.49 (m) C-18, C-25 
22 29.01   
23 28.74 1.40 (m)  
24 28.52   
25 28.46   
26 28.31 1.27 (m)  
27 28.16   
28 25.95   
29 25.85   
30a 25.56 1.44 (m)  
30b  1.35 (m)  
31a 22.53 2.53 (m) C-2, C-4, C-23/27 
31b  2.46 (m) C-1, C-4, C-23/27 
32 22.00   
33a 21.98 0.86 (t, 7.0)  
33b  1.27 (m) C-19, C-34 
34 13.91   
35 13.87 0.86 (t, 7.0) C-20, C-32 
a 
Numbering is for reference purposes, only. 
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4.2.4  Compounds F-6.3.2, F-6.3.3 and F-6.3.8 
 
E13010 F-6.3.2, a colorless amorphous solid UV MeOH [absorption maxima at = 
205 nm (log= 4.26), = 229 nm (log= 4.31), = 245 nm (log= 4.32), = 257 nm 
(log= 4.30)]; the HR-ESI-MS showed an [M - H]- m/z 683.4271, calculated 683.4289 for 
C38H64ClO8. From Figure 12A, the retention time of this compound was of 8.62 minutes. 
For this compound, due to its low amount, it was only possible to obtain the 1H NMR 
spectra (Figure 17A). 
E13010 F-6.3.3, a colorless amorphous solid UV MeOH [absorption maxima at = 
205 nm (log= 4.62), = 229 nm (log= 4.66), = 245 nm (log= 4.67), = 257 nm 
(log= 4.65)]; the HR-ESI-MS established an [M - H]- m/z 645.3680, calculated 645.3688 
for C35H59Cl2O6. The retention time of this compound was of 8.76 minutes as shown in 
Figure 12A. For this compound it was also only possible to obtain the 1H NMR spectra 
(Figure 17B). Comparing compound F-6.3.3 with the main compound (F-5.4), it appears to 
correspond to the loss a methylene (CH2) due to the decrease of m/z 14.0158. 
E13010 F-6.3.8, a colorless amorphous solid UV MeOH [absorption maxima at = 
205 nm (log= 4.18), = 229 nm (log= 4.22), = 245 nm (log= 4.23), = 257 nm 
(log= 4.21)]; established the same [M - H]- as compound F-5.4 for the main peak 
obtained for the peak with a retention time of 10.37 minutes, indicating the great similarity 
between these compounds. However, this compound appears not to be completely pure 
due to the presence of peaks at 10.10, 10.29 and 10.67 minutes. In Figure 18 the 1H NMR 
spectra of this compound is shown. Again, given the NMR data and HR-MS data 
(molecular formula), these are members of the same family of compounds, although their 
precise structure is, at the moment, unknown. 
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Figure 17 – 
1
H-NMR spectra of compound F-6.3.2 (A) and F-6.3.3 (B) in CDCl3 (recorded 
at 600 MHz). 
 
  
Tiago Afonso  2014 
43 
 
 
Figure 18 – 
1
H-NMR spectra of compound F-6.3.8 in CDCl3 (recorded at 600 MHz). 
 
4.5 IC50 of the compounds 
 
To calculate the IC50 of the compounds, a similar procedure as the one used to 
measure bioactivity in the cancer cell lines by the MTT assay was used. The IC50 was 
calculated for the three cancer cell lines tested (RKO, MG63 and T47D) and the 
concentration interval to its determination ranged from 0.003 to 50 g mL-1. Cells were 
incubated for 48 hours, after which the absorbance was measured at 550 nm in the 
microplate reader. 
From the results obtained, the IC50 of F-5.4 (Figure 19) and F-6.2.1 (see Appendix 
I, Figure 6) for the three cancer cell lines was calculated (Table 14). 
 
Table 14 – IC50 of compounds F-5.4 and F-6.2.1 in the MG63, RKO and T47D cancer cell 
lines. 
IC50 (M) 
                  Cell line  
Compound 
MG63 RKO T47D 
F-5.4 30.5 41.3 22.7 
F-6.2.1 38.9 40.0 21.5 
 
From these values it can be said that the T47D cancer cell line showed the highest 
sensibility to these compounds whilst the RKO cell line was the least affected. 
Tiago Afonso  2014 
44 
 
For the rest of the compounds, same concentrations as these were tested, but only 
for the highest concentration (50 g mL-1) inhibition of cell viability was observed, thus not 
allowing for the IC50 values to be calculated. To calculate the IC50 values for these 
compounds, concentrations between 50 and 30 g mL-1 (first concentration with no 
observable effect tested) should have been tested, but due to the fact that almost all initial 
obtained mass of these compounds was used up, no mass was available to perform a 
new assay with the new concentrations.   
 
 
Figure 19 – Dose-response curves for compound E13010 F-5.4 in MG63 osteosarcoma 
cancer cell line (a), RKO colon carcinoma cancer cell line (b) and T47D breast carcinoma cancer 
cell line (c). 
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4.6 MarinLit search of the obtained compounds. 
 
The data obtained in this work, along with informative databases of natural 
compounds that contain analytical information, such as MarinLit (Gerwick and Moore, 
2012), allowed to promptly identifying if the compounds here obtained were already 
known or if they represent new chemical substances. The results of this search are shown 
in Table 15. 
 
Table 15 – MarinLit search for each compounds mass.   
Compound [M-H]
- 
Chemical Formula Molecular Mass MarinLit Hits 
F-5.4 659.3838 
C36H61Cl2O6 659.3845 0 
F-6.4 659.3837 
F-7.4 659.3846 
F-6.3.8 659.3832 
F-6.2.1 631.3517 C34H57Cl2O6 631.3532 0 
F-6.3.2 683.4271 C38H64ClO8 683.4289 0 
F-6.3.3 645.3680 C35H59Cl2O6 645.3688 0 
 
With no hits obtained for the masses of either compounds in the database, the 
results revealed that these are in fact new compounds that haven’t been previously 
described.  
The compounds here described are halogenated metabolites, which is frequent in 
marine cyanobacteria (Cabrita et al., 2010). Halogenation is a common modification of 
secondary metabolites and is this transformation that confers biological activity to some of 
these compounds, including anticancer activity (Neumann et al., 2008). Chlorination, such 
as what happens for the compounds here described, is the predominant modification, 
followed by bromination, which reflects the high presence of chloride, and, to a less 
extent, bromide ions in seawater (Neumann et al., 2008; Cabrita et al., 2010). As a result, 
chlorine and bromine seem to be the major halogens used to raise biological activity of 
secondary metabolites (Cabrita et al., 2010).  
For the majority of the bioactive secondary metabolites, a natural role is yet to be 
described. Some appear to have a protective role against predators, acting as feeding 
deterrants or toxins, or of competition with other organisms for resources such as light, 
space or nutrients (Nagle and Paul, 1999; Berry et al., 2008).  These could be one of the 
reasons why this strain produces these newly discovered compounds. 
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Although the compounds here described showed low to moderate activity against 
cancer cell lines, it is still the beginning of unraveling the possible topics of research and 
applications that these bioactive compounds might have. Despite their only moderate 
bioactivity, further studies of the biological processes in which they cause inhibition; on 
their total structure characterization and comprehending their total synthesis could reveal 
a wide range of applications.  
From total synthesis, new chemical architectures allow investigators to develop 
new analogs that may be more efficient as anticancer agents (Zhang et al., 2011). 
Structure-activity relationship studies might help with this objective in the future (Zhang et 
al., 2011).   
The discovery of new compounds is also important in the area of biocatalysis. By 
encoding enzymes that catalyse a variety of reactions, nature produces an extremely wide 
range of biomolecules that display bioactivity, which may then be used in synthetic biology 
(Michels et al., 1998; Rich et al., 2002). 
New natural compounds are also important to study cellular processes, being used 
as molecular tools or biological probes, such as epoxomicin, a potent proteasome 
inhibitor, which is a helpful tool for the discernment of proteasome biology (Sin et al., 
1999). In fact, epoxomicin is now widely used as one of the main inhibitors of proteasome 
activity in standard proteasome cell based assays (Moravec et al., 2009). Many more 
similar examples exist.    
For all these reasons and applications, several further studies on different 
molecular targets should be performed for the new compounds described in this work in 
order to elucidate their full potential. 
 
4.7 Extraction and fractionation of Uncultured Chroococcales strain 
LEGE 10410 
 
From 14.2 g (d.w.) of S. salina biomass, a 4.23% yield (0.6 g) of crude extract was 
obtained. To this extraction the code E14027 was designated. Following normal phase 
chromatography of the E14027 crude extract, nine fractions were obtained (A-I). All 
fractions were subjected to the MTT assay, enzymatic assays and to an antimicrobial 
susceptibility screening assay.  
The results obtained from the MTT assay revealed no significant effects regarding 
the decrease in cell inhibition in either cancer cell lines tested at the concentration of both 
30 and 3 g mL-1 (see Appendix I, Figure 5). 
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Regarding the HDAC enzymatic assay, there was no inhibition of histone 
deacetylase by either fraction at the tested concentration. 
Results from the Proteasome enzymatic assay revealed that fraction F was the 
one that showed higher inhibition for the chymotrypsin-like (Figure 20) and caspase-like 
proteolytic activities (Figure 21). Other fractions also revealed some inhibitory effects such 
as fractions E, G and H for the caspase-like proteolytic activity (Figure 21). For the trypsin-
like proteolytic activity, no fraction revealed inhibitory effects. 
 
 
Figure 20 – Chymotrypsin-like proteasome activity when tested with E14010 VLC fractions 
(A-I). Fractions tested at a final concentration of 3 g mL
-1
. The proteasome inhibitor epoxomicin 
was used for the positive control.   
 
Figure 21 – Caspase-like proteasome activity when tested with E14010 VLC fractions (A-
I). Fractions tested at a final concentration of 3g mL
-1
. The proteasome inhibitor epoxomicin was 
used for the positive control (the used concentration was not sufficient to cause inhibition).   
 
From the antimicrobial susceptibility screening assay, fraction F revealed to be the 
most interesting, showing inhibition halos in C. albicans and in all tested bacteria except 
S. aureus. Fractions E, G and I also revealed inhibition halos in C. albicans, being this the 
most sensitive specie to the compounds tested in this assay (Figure 22).  
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Although some fractions revealed bioactivity in this assays, especially fraction F, 
the mass collected from the normal phase chromatography for each fraction was low. The 
mass of the most interesting fractions here tested were 8.5 mg for fraction E, 2.1 mg for 
fraction F and 0.6 mg for fraction G, thus rendering further studies impracticable before re-
extraction of the strains biomass. Fraction I (187.0 mg), in a ratio between mass and 
bioactivity, showed more promise to lead to the possible isolation of bioactive compounds. 
This will constitute future work in our laboratory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 – Antibiogram of C. albicans exposed to E14027 VLC fractions (A-I). Each blank 
disk was impregnated with 15L of a 1 mg mL
-1
 solution (DMSO). DMSO was used as the 
negative control. 
 
4.8 Molecular identification of Uncultured Chroococcales strain 
LEGE 10410 
 
The portion of the DNA that codifies ribosomal RNA (rRNA) in the smallest portion 
of the ribosome (16S) has been broadly used in molecular identification, since it has an 
ubiquitous distribution among the prokaryotic group (Otsuka et al., 1998; Wilson et al., 
2000). This portion, designated 16S rRNA, although being conserved in the prokaryotes, 
presents some variation, thus showing the ability to confer specificity to the groups of 
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which it belongs (Lyra et al., 2001; Falcon et al., 2002). This gene, besides distinguishing 
species of a certain genus, can also differentiate strains in a species (Sangolkar et al., 
2006). 
The pair of primers 359F/781R was used to amplify the 16S rRNA gene and, after 
sequencing the resulting amplicon (Figure 23) and searching it in the BLASTn database, 
the strain LEGE 10410 was identified as belonging to the genus Chroococcidiopsis. The 
determination of the genus was based on a combination of the maximum score (758) and 
the percent similarity (99%). 
 
GGGGAATCTTCCGCAATGGGCGAAAGCCTGACGGAGCAATACCGCGTGAGGGAGGAAGGCTTTTGGGTTGTAAACCTCTTT
TATCAAGGAAGAAGAAAGTGACGGTACTTGAAGAATCAGCATCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGA
TGCAAGCGTTATCCGGAATCATTAGGCGTAAAGCGTCCGCAGGTGGTGGTTCAAGTCTGCTGTTAAAGACAGAAGCTCAAC
TTCTGAGCGGCAGTGGAAACTGGGCAACTAGAGTACGGTAGGGGTTGAGGGAATTCCCAGTGTAGCGGTGAAATGCGTAGA
TATTGGGAAGAACACCAGTGGCGAAGGCGCTCAACTGGGCCGTAACTGACACTCAGGGACGAAAGCTAGGGTAGCGAATGG
GATTAGATACCCCAGTAGTC 
 Figure 23 – Amplicon obtained from the 16S rRNA gene for the strain LEGE 10410. 
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5. Conclusion 
In this work we discovered a family of different compounds obtained from the 
cyanobacterial strain Synechocystis salina LEGE 06099 with moderate anticancer activity. 
These results confirm what previous studies revealed, unicellular free-ling species have 
the ability to produce a variety of bioactive compounds with interesting bioactivity. 
Although the compounds here described showed only low to moderate activity 
against cancer cell lines, it doesn’t exclude the possibility that, by the reasons previously 
mentioned, these metabolites could have other interesting activities against different 
molecular targets. For this reason, more studies on different molecular targets should be 
performed for these new compounds in order to elucidate their full potential. 
Also, as there are many more cyanobacterial strains currently being overlooked, 
the results here obtained reveal the necessity to continue with this line of work in order to 
potentially discover new interesting natural substances.  
The next step will be to fully characterize the structures of the compounds here 
described, and try to discover the mode of action in which they cause growth inhibition on 
the cancer cell lines, as well as to continue to fractionate and possibly isolate new 
compounds from Chroococcidiopsis sp. LEGE 10410. 
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7. Appendix 
7.1 Appendix I – MTT viability assays (96 well plates; 3.3 x 104 cells per 
well; 4 hours exposure to MTT). 
 
 
 
Figure 1 – Cell viability (% of negative control) from E13010 Fraction F sub-fractions (F-2 – 
F-12) with the concentration of 30 g mL
-1
(*) and 3 g mL
-1
 on the RKO (a), MG63 (b) and T47D 
(c) cancer cell lines, with two exposure times, 24H and 48H at 3.3 x 10
4
 cells per well. Negative 
control corresponded to 1% DMSO and positive control to 20% DMSO. 
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Figure 2 – Cell viability (% of negative control) from E13010 Fraction F-5 sub-fractions (F-
5.1 – F-5.10) with the concentration of 30 g mL
-1
(*) and 3 g mL
-1
 on the RKO (a), MG63 (b) and 
T47D (c) cancer cell lines, with two exposure times, 24H and 48H at 3.3 x 10
4
 cells per well. 
Negative control corresponded to 1% DMSO and positive control to 20% DMSO.  
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Figure 3 – Cell viability (% of negative control) from E13010 Fraction F-6 sub-fractions (F-
6.1 – F-6.12) with the concentration of 30 g mL
-1
(*) and 3 g mL
-1
 on the RKO (a), MG63 (b) and 
T47D (c) cancer cell lines, with two exposure times, 24H and 48H at 3.3 x 10
4
 cells per well. 
Negative control corresponded to 1% DMSO and positive control to 20% DMSO.  
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Figure 4 – Cell viability (% of negative control) from E13010 Fraction F-6.2; F-6.3 and F-7 
sub-fractions with the concentration of 30 g mL
-1
(*) and 3 g mL
-1
 on the RKO (a), MG63 (b) and 
HT29 (c) cancer cell lines, with two exposure times, 24H and 48H at 3.3 x 10
4
 cells per well. 
Negative control corresponded to 1% DMSO and positive control to 20% DMSO.  
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Figure 5 – Cell viability (% of negative control) from E14027 VLC Fractions (A-I) with the 
concentration of 30 g mL
-1
(*) and 3 g mL
-1
 on the RKO (a) and MG63 (b) cancer cell lines, with 
two exposure times, 24H and 48H at 3.3 x 10
4
 cells per well. Negative control corresponded to 1% 
DMSO and positive control to 20% DMSO (T47D cell line had growing problems*).  
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Figure 6 – Dose-response curves obtained for compound E13010 F-6.2.1 in MG63 
osteosarcoma cancer cell line (a), RKO colon carcinoma cancer cell line (b) and T47D breast 
carcinoma cancer cell line (c). 
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7.2 Appendix II – 2D NMR data of compounds F-5.4, F-6.2.1 and F-7.4.  
 
Figure 1 – HSQC (A) and HMBC (B) spectra of compound F-5.4/F-6.4 in CDCl3 (recorded 
at 400 MHz). 
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Figure 2 – COSY (A) and NOESY (B) spectra of compound F-5.4/F-6.4 in CDCl3 (recorded 
at 400 MHz). 
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Figure 3 – HSQC (A) and HMBC (B) spectra of compound F-6.2.1 in DMSO-d6 (recorded 
at 600 MHz). 
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Figure 4 – COSY spectra of compound F-6.2.1 in DMSO-d6 (recorded at 600 MHz). 
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Figure 5 – HSQC (A) and HMBC (B) spectra of compound F-7.4 in DMSO-d6 (recorded at 
600 MHz). 
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Figure 6 – COSY spectra of compound F-7.4 in DMSO-d6 (recorded at 600 MHz). 
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7.3 Appendix III – UV-Vis data for each compound. 
 
Figure 1 – UV-Vis spectra of compound F-5.4 in MeOH (Absorption maxima were 
registered at 205, 229, 245 and 257 nm). 
 
 
Figure 2 – UV-Vis spectra of compound F-6.2.1 in MeOH (Absorption maxima were 
registered at 205, 229, 245 and 257 nm). 
 
Figure 3 – UV-Vis spectra of compound F-6.3.2 in MeOH (Absorption maxima were 
registered at 205, 229, 245 and 257 nm). 
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Figure 4 – UV-Vis spectra of compound F-6.3.3 in MeOH (Absorption maxima were 
registered at 205, 229, 245 and 257 nm). 
 
Figure 5 – UV-Vis spectra of compound F-6.3.8 in MeOH (Absorption maxima were 
registered at 205, 229, 245 and 257 nm). 
 
Figure 6 – UV-Vis spectra of compound F-7.4 in MeOH (Absorption maxima were 
registered at 205, 229, 245 and 257 nm). 
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